A nomogram for predicting the HER2 status in female patients with breast cancer in China: a nationwide, multicenter, 10-year epidemiological study-Reference-Cited by-同舟云学术

A nomogram for predicting the HER2 status in female patients with breast cancer in China: a nationwide, multicenter, 10-year epidemiological study

Published:2019-05-04 Issue:1 Volume:14 Page:
ISSN:1746-1596
Container-title:Diagnostic Pathology
language:en
Short-container-title:Diagn Pathol

Author:

Zhang Huimin,Xie Peiling,Li Zhuoying,Huang Rong,Feng Weiliang,Kong Yanan,Xu Feng,Zhao Lin,Song Qingkun,Li Jing,Zhang Baoning,Fan Jinhu,Qiao Youlin,Xie Xiaoming,Zheng Shan,He Jianjun,Wang Ke

Publisher

Springer Science and Business Media LLC

Subject

General Medicine,Histology,Pathology and Forensic Medicine

Link

http://link.springer.com/content/pdf/10.1186/s13000-019-0806-4.pdf

Reference24 articles.

1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424.

2. Generali D, Ardine M, Strina C, Milani M, Cappelletti MR, Zanotti L, et al. Neoadjuvant treatment approach: the Rosetta stone for breast Cancer? J Natl Cancer Inst Monogr. 2015;2015(51):32–5.

3. Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013;24(9):2278–84.

4. Gianni L, Pienkowski T, Im YH, Roman L, Tseng LM, Liu MC, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;17(6):25–32.

5. De AE, Holmes AP, Piccartgebhart M, Holmes E, Di CS, Swaby RF, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. Lancet Oncol. 2014;15(10):1137–46.